{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.22","upperLimit":"4.62","value":"2.20"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"title":"Change in MCS score at Week 12, n=82"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.05","upperLimit":"4.53","value":"2.29"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"}],"units":"Participants"}],"title":"Change in MCS score at Week 24, n=75"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-10.55","upperLimit":"2.96","value":"-3.80"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Change in MCS score at end of study, n=20"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-2.86","upperLimit":"0.36","value":"-1.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"title":"Change in PCS score at Week 12, n=82"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-3.75","upperLimit":"-0.05","value":"-1.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"}],"units":"Participants"}],"title":"Change in PCS score at Week 24, n=75"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-7.39","upperLimit":"1.66","value":"-2.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Change in PCS score at end of study, n=20"}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"The SF-36 Health Survey (Version 2) uses patient-reported symptoms on 8 subscales to assess health-related quality of life (HRQoL). The Physical Component Summary (PCS) score summarizes the subscales Physical Functioning, Role-Physical, Bodily Pain, and General Health. The Mental Component Summary (MCS) score summarizes the subscales Vitality, Social Functioning, Role-Emotional, and Mental Health. Each score was scaled from 0 to 100. A positive change score indicates better HRQoL.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received vismodegib 150 mg orally once daily until disease progression; intolerable toxicity, most probably attributable to vismodegib; or withdrawal from the study.","id":"OG000","title":"Metastatic and Locally Advanced Basal-Cell Carcinoma"}],"paramType":"MEAN","populationDescription":"Efficacy-evaluable population: All treated patients for whom the independent pathologist's interpretation of archival tissue or baseline biopsies was consistent with basal cell carcinoma. Number analyzed (n) reflects the number of participants with both baseline and visit data available for a given timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12, Week 24, and at the end of the study or early termination visit (up to the clinical cutoff date of 26 November 2010, up to 90 weeks)","title":"Change From Baseline in Short Form 36 (SF-36) Health Survey Scores","type":"SECONDARY","unitOfMeasure":"Units on a scale"}